talazoparib plus enzalutamide shows improvement in pfs over soc in first-line hrr mcrpc
Published 1 year ago • 272 plays • Length 5:01Download video MP4
Download video MP3
Similar videos
-
14:30
mcrpc care: reducing progression risk by combining enzalutamide and talazoparib
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
0:52
talapro-2 study design for 1l in mcrpc patients - now fda approved | #oncology #cancer #2023
-
1:56
talapro-2: exposure efficacy of talazoparib and enzalutamide in mcrpc
-
1:02
dr. agarwal on the safety profile of enzalutamide/talazoparib in mcrpc
-
8:56
talapro-2: phase 3 results of talazoparib plus enzalutamide for mcrpc
-
7:00
comparing the second generation hormone therapies | ask a prostate expert, mark scholz, md
-
5:19
xtandi patient stories
-
13:24
enzalutamide approved for prostate cancer with biochemical recurrence: stephen freedland, md
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
2:26
caspar: the addition of rucaparib to enzalutamide for the treatment of mcrpc
-
0:46
ctc hoxb13 rna in mcrpc: abiraterone/enzalutamide impact
-
1:39
dr. howard scher on corticosteroids during treatment with enzalutamide in mcrpc
-
4:35
support for continuing enzalutamide after mcrpc progression | axel merseburger
-
4:17
cheiron study: docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patie...
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
-
9:29
implications of the fda approval of combination talazoparib & enzalutamide therapy
-
8:12
the use of abiraterone and enzalutamide against crpc
-
2:50
prosper: enzalutamide vs. placebo for nmcrpc